Indefinite Delivery Contract HHSD200201689087I

This federal contract IDV award is a multiple-award Indefinite Delivery Contract between the Centers for Disease Control and Prevention (CDC) and Pfizer Inc., a global pharmaceutical manufacturer. The $117,849,500 contract, with a performance period ending June 30, 2026, is for the delivery of adult vaccines under the CDC's VACCINES program. As the prime contractor, Pfizer will provide a range of pharmaceutical products to multiple federal healthcare agencies, including the Department of...

This Indefinite Delivery Contract (IDC) with a ceiling value of $347,200,000.00 was awarded to Pfizer Inc. on June 1, 2024 by the Centers for Disease Control and Prevention (CDC) to provide COVID-19 adult vaccines. The contract has a period of performance through September 30, 2025 and was awarded without any set-aside designation, reflecting Pfizer's status as a large pharmaceutical corporation. Under this IDC, Pfizer will supply a variety of adult vaccines to support the CDC's public health...

This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Sanofi Pasteur Inc., a foreign-owned, for-profit pharmaceutical manufacturer specializing in vaccines and medical supplies. The $15,226,000 multiple-award contract covers the procurement of adult COVID-19 vaccines for the period of June 1, 2025 through May 31, 2026. As a leading global vaccine provider, Sanofi Pasteur has secured numerous significant IDCs across various federal...

This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Pfizer Inc. to purchase a variety of pediatric vaccines for the Vaccines for Children (VFC) program. The $1.5 billion contract has a period of performance from April 1, 2023 to March 31, 2024. The contract will procure a minimum of 100 doses up to maximum quantities ranging from 100,000 to 13 million doses for 21...

Pfizer Inc. is providing adult vaccines to the Centers for Disease Control and Prevention under a multiple award indefinite delivery contract. The contract was awarded on July 1, 2020 with a potential value of $48.8 million. Pfizer will supply vaccines for hepatitis A & B, pneumococcal disease, tetanus, diphtheria, herpes zoster, pertussis, measles, mumps, rubella, meningitis, human papillomavirus, varicella, and serogroup B meningococcal disease. Delivery will support immunization...

This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian federal agency, to Pfizer Inc., a large pharmaceutical manufacturer, on June 1, 2025. The $458,750,000 multiple-award contract has an ultimate completion date of May 31, 2026 and is for the procurement of adult COVID-19 vaccines. As a prime contractor, Pfizer will be responsible for supplying the CDC's Pittsburgh location with the necessary COVID-19 vaccine products over the...

The provided information describes an Indefinite Delivery Contract (IDC) awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a leading global pharmaceutical corporation. The $425.5 million IDC, with a period of performance running from June 2023 to June 2024, is for the procurement of adult COVID-19 vaccines. As a major supplier of pharmaceutical products and vaccines to the U.S. federal government, Pfizer holds several significant Indefinite Delivery Vehicles (IDVs),...

This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a large pharmaceutical manufacturer, to provide a range of standard pediatric vaccines to support immunization programs under the Vaccines for Children (VFC) program and Section 317(j) of the Public Health Service Act. The $1.6 billion multiple-award IDC has a period of performance from April 1, 2021 through March 31, 2022, with no small business set-asides utilized. The...

This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a large pharmaceutical manufacturer, to procure a variety of pediatric vaccines for the Vaccines for Children (VFC) program. The contract has a ceiling value of $1,914,795,500.00 and a period of performance from April 1, 2024 through March 31, 2025. The solicitation sought offers for 27 different pediatric vaccines including vaccines for diseases such as dengue, diphtheria,...

This indefinite delivery contract, awarded by the Centers for Disease Control and Prevention (CDC) to Sanofi Pasteur Inc., is for the provision of vaccines for the Vaccines for Children (VFC) program. Valued at up to $2,413,810,030, the 5-year contract (4/1/2023 - 3/31/2024) is a multiple award vehicle that allows the CDC to issue task orders for a variety of vaccine products and related services from the prime contractor. Sanofi Pasteur, as a leading global vaccine manufacturer, will leverage...